Zeo ScientifiX (ZEOX) awards 175,000 restricted shares to top executives

Rhea-AI Filing Summary

Zeo ScientifiX, Inc. awarded equity incentives to two senior executives. On January 14, 2026, the company granted 175,000 restricted shares of common stock under its 2021 Incentive Stock Plan to each of Ian Bothwell, who serves as Chief Executive Officer, Chief Financial Officer and director, and Dr. George Shapiro, the Chief Medical Officer and a director. These restricted shares are designed to vest over time, with 50% vesting on the eighth-month anniversary of the award date and the remaining 50% vesting on the one-year anniversary. This structure encourages ongoing service and aligns the executives’ interests with the company’s long-term performance.

false 0001557376 0001557376 2026-01-14 2026-01-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 14, 2026

ZEO SCIENTIFIX, INC.

(Exact name of registrant as specified in its charter)

Nevada		000-55008		47-4180540
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3321 College Avenue, Suite 246 Davie, Florida		33314
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (888) 963-7881

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each Class		Trading Symbol		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,” “ZEO,” “we,” “us” and “our” refer to Zeo ScientifiX, Inc.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 14, 2026, the Company awarded 175,000 restricted shares of our common stock (“Shares”) under our 2021 Incentive Stock Plan to each of Ian Bothwell, our Chief Executive Officer and Chief Financial Officer and a member of the board of directors and Dr. George Shapiro, our Chief Medical Officer and a member of the board of directors. The Shares vest 50% on the eighth month anniversary of the award date and the remaining 50% on the one-year anniversary. 

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 21, 2026	ZEO SCIENTIFIX, INC.
	By:	/s/ Ian T. Bothwell
		Ian T. Bothwell Chief Executive Officer and Chief Financial Officer

2

FAQ

What executive equity awards did ZEOX disclose in this 8-K?

Zeo ScientifiX, Inc. disclosed that it granted 175,000 restricted shares of common stock to each of Ian Bothwell and Dr. George Shapiro under its 2021 Incentive Stock Plan.

Who received restricted stock grants from Zeo ScientifiX (ZEOX)?

The grants were awarded to Ian Bothwell, the company’s Chief Executive Officer, Chief Financial Officer and director, and Dr. George Shapiro, the Chief Medical Officer and a director.

How do the ZEOX restricted shares vest for the executives?

The restricted shares vest in two installments: 50% on the eighth-month anniversary of the January 14, 2026 award date and the remaining 50% on the one-year anniversary.

Under which plan were the ZEOX restricted stock awards granted?

The restricted stock awards were granted under Zeo ScientifiX’s 2021 Incentive Stock Plan, which is used to provide equity-based compensation.

What roles do the ZEOX award recipients hold at the company?

Ian Bothwell serves as Chief Executive Officer, Chief Financial Officer and a member of the board of directors, while Dr. George Shapiro is Chief Medical Officer and also a board member.